[2011-04-26] The academic conference was held in Shenyang from 7-9 April 2011. CMS sponsored the conference and invited Professor Li Weiming to deliver an academic report entitled “The Latest Development of Heart Failure Treatment”. The conference recognized the position of “XinHuoSu” in the heart failure field and serves as a new treatment and choice for heart failure patients. The conference also explained the latest research results of 7,140 cases of rhBNP clinical trials on ASCEND-HF patients, which was announced by the ACC meeting in 2010, to guarantee the safety of rhBNP and to enhance doctors` confidence to prescribe “XinHuoSu”, and also facilitated its clinical promotion and application.